Svagt Q3-resultat Nettoomsättningen ökade med 10% till 777 mkr (708) och justerad EBIT blev 2 mkr (2...
Uppvisar en mycket stabil utveckling Under det tredje kvartalet uppgick omsättningen till 182 mkr (1...
Finansiell utveckling under kvartalet Försäljningen under kvartalet uppgick till 3,2 mkr (7,2) och u...
Vitrolife’s Q3 confirms that Vitrolife is going through a period with softer organic growth, even be...
Redeye remains confident on the case, following solid Q3 numbers and the two recent Government contr...
Redey resumes coverage of Amniotics after the conclusion of the rights issue.
Ahead of Relais Q3, due on 2 November, we maintain our estimates intact.
Redeye returns with a research update on Nanologica following its Q3 2023 report, which were soft in...
Redeye comments on GiG ahead of its Q3-results (due 8 November) where we expect continued sequential...
Redeye provides an update following the Q3 report. Doro's performance exceeded our expectations, dri...
Redeye states that Catella's Q3 2022 report was weaker than expected, although the core continues to...
Redeye states the Q3 report is a good data point that the profitability "turn-around" story is under...
Redeye updates its estimates following Netmore’s Q3 report, where sales managed to beat our forecast...
Redeye updates its estimates and valuation following ADDvise releasing its Q3 2023 report.
Redeye views the performance of Tobii Dynavox favorably as the expectations continue to be exceeded.
Redeye comments on Medivir's Q3 report and on the new positive data from 18 patients in the liver ca...
3% organic growth and improved margins EBITDA down 2-5% for '23e-'25e 52-60% below historical multip...
Watch CEO Lars Lindell present the company’s Q3 report.
Management presented its quarterly earnings, adding context to the recent capital markets day (CMD),...
Another strong quarter, order intake up 33%, EBITA margin 9.
